LU92446I2 - Dolutégravir ou un sel ou solvate pharmaceutiquement acceptable de celui-ci, y compris de dolutégravir de sodium - Google Patents

Dolutégravir ou un sel ou solvate pharmaceutiquement acceptable de celui-ci, y compris de dolutégravir de sodium

Info

Publication number: LU92446I2
Authority: LU; Luxembourg
Prior art keywords: dolutegravir; solvate; pharmaceutically acceptable; acceptable salt; including sodium
Prior art date: 2005-04-28

Application number

LU92446C

Other languages

English (en)

French (fr)

Original Assignee

Shionogi & Co

Viiv Healthcare Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-04-28

Filing date

2014-05-07

Publication date

2015-10-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37215098&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92446(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-05-07 Application filed by Shionogi & Co, Viiv Healthcare Co filed Critical Shionogi & Co

2015-10-29 Publication of LU92446I2 publication Critical patent/LU92446I2/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

LU92446C 2005-04-28 2014-05-07 Dolutégravir ou un sel ou solvate pharmaceutiquement acceptable de celui-ci, y compris de dolutégravir de sodium LU92446I2 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2005131161		2005-04-28
JP2005312076		2005-10-27
PCT/US2006/016604 WO2006116764A1 (en)	2005-04-28	2006-04-28	Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity

Publications (1)

Publication Number	Publication Date
LU92446I2 true LU92446I2 (fr)	2015-10-29

Family

ID=37215098

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LU92446C LU92446I2 (fr)	2005-04-28	2014-05-07	Dolutégravir ou un sel ou solvate pharmaceutiquement acceptable de celui-ci, y compris de dolutégravir de sodium
LU00210C LUC00210I2 (xx)	2005-04-28	2021-06-15

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
LU00210C LUC00210I2 (xx)	2005-04-28	2021-06-15

Country Status (29)

Country	Link
US (22)	US8129385B2 (xx)
EP (9)	EP3187226A1 (xx)
JP (2)	JP4295353B2 (xx)
KR (4)	KR101848819B1 (xx)
AU (1)	AU2006239177B8 (xx)
BR (1)	BRPI0610030B8 (xx)
CA (1)	CA2606282C (xx)
CY (7)	CY1115151T1 (xx)
DK (6)	DK3372281T3 (xx)
EA (1)	EA014162B1 (xx)
ES (7)	ES2446324T3 (xx)
FI (1)	FIC20210017I1 (xx)
FR (1)	FR14C0041I2 (xx)
HK (4)	HK1107227A1 (xx)
HU (6)	HUE044978T2 (xx)
IL (4)	IL186555A (xx)
LT (4)	LT3045206T (xx)
LU (2)	LU92446I2 (xx)
MA (1)	MA29460B1 (xx)
MX (2)	MX302718B (xx)
NL (2)	NL300676I2 (xx)
NO (5)	NO339525B1 (xx)
NZ (1)	NZ562339A (xx)
PL (5)	PL3045206T3 (xx)
PT (5)	PT2465580E (xx)
SI (6)	SI3045206T1 (xx)
TW (1)	TWI378931B (xx)
VN (1)	VN34404A1 (xx)
WO (1)	WO2006116764A1 (xx)

Families Citing this family (145)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005061513A1 (en)	2003-12-24	2005-07-07	Biota Scientific Management Pty Ltd	Polycyclic agents for the treatment of respiratory syncytial virus infections
US7273859B2 (en) *	2004-05-12	2007-09-25	Bristol-Myers Squibb Company	HIV integrase inhibitors: cyclic pyrimidinone compounds
PL3045206T3 (pl)	2005-04-28	2018-08-31	Viiv Healthcare Company	Wielopierścieniowe pochodne karbamoilopirydonu wykazujące aktywność inhibitorową wobec integrazy HIV
JP4982482B2 (ja)	2005-05-10	2012-07-25	メルク・シャープ・エンド・ドーム・コーポレイション	Ｈｉｖインテグラ−ゼ阻害剤
JP5094725B2 (ja)	2005-10-04	2012-12-12	イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ	Ｈｉｖインテグラーゼ阻害剤
BRPI0617842A2 (pt) *	2005-10-27	2011-08-09	Shionogi & Co	composto ou um sal farmaceuticamente aceitável ou um solvato do mesmo, e, composição farmacêutica
TWI423972B (zh)	2006-09-28	2014-01-21	Biota Scient Management	治療呼吸系融合細胞病毒感染之多環劑
EP2220076B1 (en)	2007-11-15	2012-01-18	Boehringer Ingelheim International GmbH	Inhibitors of human immunodeficiency virus replication
CN102124011A (zh)	2007-11-15	2011-07-13	贝林格尔.英格海姆国际有限公司	人类免疫缺陷病毒复制的抑制剂
MX2010005334A (es)	2007-11-16	2010-05-27	Boehringer Ingelheim Int	Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
WO2010011818A1 (en) *	2008-07-25	2010-01-28	Smithkline Beecham Corporation	Chemical compounds
DK2320908T3 (en) *	2008-07-25	2014-03-10	Viiv Healthcare Co	DOLUTEGRAVIR prodrugs
WO2010011816A1 (en) *	2008-07-25	2010-01-28	Smithkline Beecham Corporation	Chemical compounds
WO2010011815A1 (en) *	2008-07-25	2010-01-28	Smithkline Beecham Corporation	Chemical compounds
CN105198804B (zh)	2008-07-25	2018-03-23	盐野义制药株式会社	用作hiv整合酶抑制剂的化合物
AU2014277831C1 (en) *	2008-12-11	2022-10-06	Shionogi & Co. Ltd.	Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
EP2370419B1 (en) *	2008-12-11	2017-09-27	Shionogi&Co., Ltd.	Maltol ether processes and intermediates
KR101733625B1 (ko) *	2008-12-11	2017-05-10	시오노기세야쿠 가부시키가이샤	카르바모일피리돈 ｈｉｖ 인테그라제 억제제 및 중간체의 합성
JP5572168B2 (ja)	2008-12-11	2014-08-13	ビーブ・ヘルスケア・カンパニー	カルバモイルピリドンｈｉｖインテグラーゼ阻害剤の製造方法および中間体
TWI518084B (zh)	2009-03-26	2016-01-21	鹽野義製藥股份有限公司	哌喃酮與吡啶酮衍生物之製造方法
RS57244B1 (sr)	2009-06-15	2018-07-31	Shionogi & Co	Supstituisani policiklički derivati karbamoilpiridona
WO2011011483A1 (en) *	2009-07-22	2011-01-27	Glaxosmithkline Llc	Chemical compounds
JP5624148B2 (ja)	2009-10-13	2014-11-12	エランコ・アニマル・ヘルス・アイルランド・リミテッド	大環状インテグラーゼ阻害剤
KR101830715B1 (ko) *	2010-01-27	2018-04-04	비이브 헬쓰케어 컴퍼니	Hiv 감염을 치료하기 위한 약학적 조합물
AU2014202404C1 (en) *	2010-01-27	2022-06-23	Viiv Healthcare Company	Antiviral therapy
AU2014202405B2 (en) *	2010-01-27	2016-02-25	Viiv Healthcare Company	Antiviral therapy
TWI508968B (zh) *	2010-02-08	2015-11-21	Biota Scient Management	用於治療呼吸道融合性病毒感染的化合物
AU2011221037A1 (en) *	2010-02-26	2012-09-06	Japan Tobacco Inc.	1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine derivative and use of same as HIV integrase inhibitor
TWI582097B (zh)	2010-03-23	2017-05-11	Ｖｉｉｖ醫療保健公司	製備胺甲醯吡啶酮衍生物及中間體之方法
WO2011121105A1 (en)	2010-04-02	2011-10-06	Tibotec Pharmaceuticals	Macrocyclic integrase inhibitors
WO2011129095A1 (ja) *	2010-04-12	2011-10-20	塩野義製薬株式会社	インテグラーゼ阻害活性を有するピリドン誘導体
US9073941B2 (en)	2010-06-28	2015-07-07	Academia Sinica	Compounds and methods for treating tuberculosis infection
PT3456721T (pt)	2010-08-05	2021-05-04	Shionogi & Co	Método de produção de compostos possuindo atividade inibitória de integrase de vih
TWI577377B (zh) *	2010-09-16	2017-04-11	Ｖｉｉｖ醫療保健公司	醫藥組合物
CN103228653B (zh) *	2010-09-24	2016-03-16	盐野义制药株式会社	被取代的多环性氨基甲酰基吡啶酮衍生物的前药
US8796303B2 (en)	2010-11-26	2014-08-05	Biota Scientific Management Pty Ltd.	Imidazo[2,1-G][1,7]naphthyridines for treating respiratory syncytial virus infections
US20140213553A1 (en) *	2011-05-03	2014-07-31	Concert Pharmaceuticals Inc.	Carbamoylpyridone derivatives
PL2742051T3 (pl) *	2011-09-14	2017-06-30	Mapi Pharma Limited	Amorficzna postać soli sodowej dolutegrawiru
WO2013054862A1 (ja)	2011-10-12	2013-04-18	塩野義製薬株式会社	インテグラーゼ阻害活性を有する多環性ピリドン誘導体
CA2860323C (en)	2011-12-28	2022-03-08	The Regents Of The University Of California	Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
ES2790358T3 (es)	2011-12-28	2020-10-27	Global Blood Therapeutics Inc	Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular
US9714243B2 (en)	2012-12-17	2017-07-25	Merck Sharp & Dohme Corp.	4-pyridinonetriazine derivatives as HIV integrase inhibitors
KR20230061576A (ko) *	2012-12-21	2023-05-08	길리애드 사이언시즈, 인코포레이티드	폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
JP6320039B2 (ja)	2012-12-27	2018-05-09	日本たばこ産業株式会社	置換されたスピロピリド［１，２−ａ］ピラジン誘導体及びそのＨＩＶインテグラーゼ阻害剤としての医薬用途
WO2014125124A1 (en)	2013-02-18	2014-08-21	Ratiopharm Gmbh	Solid pharmaceutical dosage form of dolutegravir
EP2767272A1 (en)	2013-02-18	2014-08-20	Ratiopharm GmbH	Solid pharmaceutical dosage form of dolutegravir
WO2014128545A2 (en)	2013-02-19	2014-08-28	Aurobindo Pharma Limited	An improved process for the preparation of dolutegravir
US9458139B2 (en)	2013-03-15	2016-10-04	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en)	2013-03-15	2019-04-23	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
JP6463327B2 (ja)	2013-03-15	2019-01-30	グローバルブラッドセラピューティクスインコーポレイテッド	ヘモグロビンの修飾のための化合物及びその使用
US8952171B2 (en)	2013-03-15	2015-02-10	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en)	2013-03-15	2016-08-23	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en)	2013-03-15	2017-03-28	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en)	2013-03-15	2017-10-31	Global Blood Therapeutics, Inc.	Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en)	2013-03-15	2014-09-18	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
EP2968299B1 (en)	2013-03-15	2021-01-20	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
WO2014145040A1 (en)	2013-03-15	2014-09-18	Global Blood Therapeutics, Inc.	Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
CN105073728A (zh)	2013-03-15	2015-11-18	全球血液疗法股份有限公司	化合物及其用于调节血红蛋白的用途
US9493479B2 (en)	2013-04-16	2016-11-15	Merck Sharp & Dohme Corp.	Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors
US9951079B2 (en) *	2013-06-13	2018-04-24	Merck Sharp & Dohme Corp.	Fused tricyclic heterocyclic compounds as HIV integrase inhibitors
EP3016935B1 (en)	2013-07-04	2018-09-05	Hetero Research Foundation	Process for the preparation of intermediate of dolutegravir
NO2865735T3 (xx) *	2013-07-12	2018-07-21
RS56540B1 (sr)	2013-07-12	2018-02-28	Gilead Sciences Inc	Policiklična karbamoilpiridonska jedinjenja i njihova upotreba za lečenje hiv infekcija
EP3022209B1 (en)	2013-07-17	2018-03-07	ratiopharm GmbH	Dolutegravir potassium salt
WO2015019310A1 (en)	2013-08-07	2015-02-12	Mylan Laboratories Ltd	Process for the preparation of dolute-gravir and intermediates thereof
WO2015039348A1 (en) *	2013-09-23	2015-03-26	Merck Sharp & Dohme Corp.	Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
MX367057B (es) *	2013-09-27	2019-08-02	Merck Sharp & Dohme	Derivados de quinolizina sustituidos utiles como inhibidores de integrasa del vih.
EA201992707A1 (ru)	2013-11-18	2020-06-30	Глобал Блад Терапьютикс, Инк.	Соединения и их применения для модуляции гемоглобина
WO2015092752A1 (en)	2013-12-20	2015-06-25	Mylan Laboratories Ltd.	Novel crystalline form of dolutegravir sodium
WO2015089847A1 (en) *	2013-12-20	2015-06-25	Merck Sharp & Dohme Corp.	Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
US9808428B2 (en)	2014-01-14	2017-11-07	Board Of Regents Of The University Of Nebraska	Compositions and methods for the delivery of therapeutics
EP3096763B1 (en) *	2014-01-21	2019-12-25	Laurus Labs Limited	Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
AP2016009261A0 (en)	2014-02-07	2016-06-30	Global Blood Therapeutics Inc	Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
CN106866702B (zh) *	2014-03-19	2019-03-19	杭州普晒医药科技有限公司	德罗格韦钠盐的晶型及其制备方法
WO2015140569A1 (en)	2014-03-20	2015-09-24	Cipla Limited	Pharmaceutical composition
ZA201503540B (en) *	2014-05-20	2016-10-26	Cipla Ltd	Process for preparing polycyclic carbamoyl pyridone derivatives
TW201613936A (en)	2014-06-20	2016-04-16	Gilead Sciences Inc	Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (xx) *	2014-06-20	2018-06-23
TWI744723B (zh) *	2014-06-20	2021-11-01	美商基利科學股份有限公司	多環型胺甲醯基吡啶酮化合物之合成
WO2016027879A1 (ja) *	2014-08-22	2016-02-25	塩野義製薬株式会社	インテグラーゼ阻害活性を有する多環性ピリドン誘導体
EP3203995A4 (en)	2014-10-09	2019-05-15	Board of Regents of the University of Nebraska	COMPOSITIONS AND METHODS OF DELIVERING THERAPY AGENTS
WO2016092527A1 (en) *	2014-12-12	2016-06-16	Sun Pharmaceutical Industries Limited	A process for the preparation of dolutegravir
TWI738321B (zh)	2014-12-23	2021-09-01	美商基利科學股份有限公司	多環胺甲醯基吡啶酮化合物及其醫藥用途
WO2016102078A1 (en)	2014-12-24	2016-06-30	Ratiopharm Gmbh	Solid state forms of dolutegravir sodium
EP3045461A1 (en)	2015-01-16	2016-07-20	LEK Pharmaceuticals d.d.	Processes for preparing dolutegravir and analogues thereof
US10730888B2 (en)	2015-02-06	2020-08-04	Mylan Laboratories Limited	Process for the preparation of dolutegravir
CZ201599A3 (cs)	2015-02-13	2016-08-24	Zentiva, K.S.	Pevné formy solí dolutegraviru a způsob jejich přípravy
WO2016154527A1 (en) *	2015-03-26	2016-09-29	Merck Sharp & Dohme Corp.	Phosphate-substituted quinolizine derivatives useful as hiv integrase inhibitors
MA41841A (fr)	2015-03-30	2018-02-06	Global Blood Therapeutics Inc	Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
PL3277691T3 (pl)	2015-04-02	2019-07-31	Gilead Sciences, Inc.	Policykliczne związki karbamoilopirydonowe i ich zastosowanie farmaceutyczne
MX2017013809A (es) *	2015-04-28	2018-03-15	Shionogi & Co	Derivados de piridona policiclica sustituida y profarmaco de los mismos.
WO2016187788A1 (en)	2015-05-25	2016-12-01	Merck Sharp & Dohme Corp.	Fused tricyclic heterocyclic compounds useful for treating hiv infection
CZ2015537A3 (cs)	2015-08-04	2017-02-15	Zentiva, K.S.	Pevné formy amorfního dolutegraviru
WO2017029642A2 (en)	2015-08-19	2017-02-23	Laurus Labs Private Limited	Novel polymorphs of dolutegravir and salts thereof
PT3346995T (pt)	2015-11-09	2019-11-22	Gilead Sciences Inc	Composições terapêuticas para o tratamento do vírus da imunodeficiência humana
EP3377066B1 (en)	2015-11-17	2021-04-07	Merck Sharp & Dohme Corp.	Amido-substituted pyridotriazine derivatives useful as hiv integrase inhibitors
MX2018006832A (es)	2015-12-04	2018-11-09	Global Blood Therapeutics Inc	Regimenes de dosificacion de 2-hidroxi-6-((2-(1-isopropil-1h-piraz ol-5-il)-piridin-3-il)-metoxi)-benzaldehido.
US10544155B2 (en)	2015-12-15	2020-01-28	Merck Sharp & Dohme Corp.	Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors
US10696636B2 (en)	2015-12-21	2020-06-30	Lupin Limited	Process for the preparation of HIV integrase inhibitors
TWI663160B (zh)	2016-05-12	2019-06-21	全球血液治療公司	用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
WO2017208105A1 (en)	2016-05-30	2017-12-07	Lupin Limited	Novel crystalline form of dolutegravir sodium
EP3474857A4 (en) *	2016-06-23	2020-03-18	VIIV Healthcare Company	COMPOSITIONS AND METHODS FOR RELEASE OF THERAPEUTIC AGENTS
ES2952878T3 (es)	2016-08-08	2023-11-06	Hetero Labs Ltd	Una composición antirretroviral multiclase
US11045423B2 (en)	2016-08-08	2021-06-29	Hetero Labs Limited	Anti-retroviral compositions
JP2019527738A (ja) *	2016-08-12	2019-10-03	ナンジンゲイターメディテックカンパニー, リミテッドNanjing Gator Meditech Company, Ltd.	プロテインキナーゼ調節剤
WO2018042332A1 (en)	2016-08-31	2018-03-08	Glaxosmithkline Intellectual Property (No.2) Limited	Combinations and uses and treatments thereof
US20190216725A1 (en) *	2016-09-21	2019-07-18	Merck Shapr & Dohme Corp.	Drug delivery system for the delivery of integrase inhibitors
TWI778983B (zh)	2016-10-12	2022-10-01	美商全球血液治療公司	包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
JOP20190130A1 (ar) *	2016-12-02	2019-06-02	Merck Sharp & Dohme	مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
BR112019011074B1 (pt)	2016-12-02	2021-01-19	Merck Sharp & Dohme Corp.	Compostos heterocíclicos tricíclicos inibidores de hiv integrase, composição que oscompreende e uso dos mesmos
WO2018109786A1 (en)	2016-12-16	2018-06-21	Cipla Limited	Novel polymoprphs and salts of polycyclic carbamoyl pyridone derivatives
US10786488B2 (en)	2017-01-26	2020-09-29	Merck Sharp & Dohme Corp.	Substituted quinolizine derivatives useful as HIV integrase inhibitors
US11040986B2 (en)	2017-02-16	2021-06-22	Sandoz Ag	Crystalline forms of cabotegravir sodium
EP3363802B1 (en)	2017-02-16	2019-11-20	Sandoz AG	Crystalline form of cabotegravir sodium
JP2020527570A (ja) *	2017-07-18	2020-09-10	ヴィーブヘルスケアカンパニー	組み合わせ薬物療法
JP7384783B2 (ja)	2017-07-21	2023-11-21	ヴィーブヘルスケアカンパニー	Ｈｉｖ感染症及びａｉｄｓを治療するためのレジメン
EP3661940A1 (en)	2017-09-07	2020-06-10	Cipla Limited	New polymorphs of dolutegravir sodium
AR113748A1 (es)	2017-10-06	2020-06-10	Shionogi & Co	Proceso estereoselectivo para preparar derivados de piridona policíclicos sustituidos
CA3126348A1 (en)	2018-01-12	2020-07-18	Board Of Regents Of The University Of Nebraska	Antiviral prodrugs and formulations thereof
WO2019159199A1 (en)	2018-02-16	2019-08-22	Cipla Limited	Continues flow process for the preparation of active pharmaceutical ingredients - polycyclic carbamoyl pyridone derivatives and intermediates thereof
WO2019199756A1 (en)	2018-04-09	2019-10-17	Board Of Regents Of The University Of Nebraska	Antiviral prodrugs and formulations thereof
CN110526930B (zh)	2018-05-23	2022-06-03	莫云芬	抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用
WO2019230857A1 (ja) *	2018-05-31	2019-12-05	塩野義製薬株式会社	多環性ピリドン誘導体
TW202323254A (zh) *	2018-05-31	2023-06-16	日商鹽野義製藥股份有限公司	多環性吡啶并三𠯤衍生物
MX2020012176A (es) *	2018-05-31	2021-01-29	Shionogi & Co	Derivado policiclico de carbamoilpiridona.
EP3820875B1 (en)	2018-07-12	2024-01-17	Laurus Labs Limited	A process for purification of protected polycyclic carbamoylpyridone derivatives
US11014884B2 (en)	2018-10-01	2021-05-25	Global Blood Therapeutics, Inc.	Modulators of hemoglobin
EP4234561A3 (en)	2018-10-22	2023-09-13	Board of Regents of the University of Nebraska	Antiviral prodrugs and nanoformulations thereof
KR20240151256A (ko)	2019-03-22	2024-10-17	길리애드 사이언시즈, 인코포레이티드	가교된 트리시클릭 카르바모일피리돈 화합물 및 그의 제약 용도
RU2717101C1 (ru) *	2019-06-03	2020-03-18	Андрей Александрович Иващенко	Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
US20200398978A1 (en)	2019-06-20	2020-12-24	Bell Helicopter Textron Inc.	Low-drag rotor blade extension
US11248005B2 (en)	2019-07-08	2022-02-15	Lupin Limited	Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor
TW202133858A (zh)	2019-11-28	2021-09-16	日商鹽野義製藥股份有限公司	以組合整合酶阻礙劑及抗ｈｉｖ藥為特徵之ｈｉｖ感染症的預防及治療用醫藥
JP2023505543A (ja)	2019-12-09	2023-02-09	ヴィーブ、ヘルスケア、カンパニー	カボテグラビルを含んでなる医薬組成物
EP4110783A1 (en)	2020-02-24	2023-01-04	Gilead Sciences, Inc.	Tetracyclic compounds for treating hiv infection
US20230218644A1 (en)	2020-04-16	2023-07-13	Som Innovation Biotech, S.A.	Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
JP2023539344A (ja)	2020-09-01	2023-09-13	ヴィーブ、ヘルスケア、カンパニー	カボテグラビルおよびレボノルゲストレルの組合せ
WO2022079739A1 (en)	2020-10-14	2022-04-21	Cipla Limited	Fixed dose compositions of cabotegravir and rilpivirine
EP4255472A2 (en)	2020-12-07	2023-10-11	VIIV Healthcare Company	Combination therapy
HUE064467T2 (hu)	2021-01-19	2024-03-28	Gilead Sciences Inc	Szubsztituált piridotriazin-származékok és alkalmazásuk
EP4389745A1 (en)	2021-06-03	2024-06-26	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	Pyridone compound having integrase inhibitory activity and pharmaceutical use thereof
CN114230579A (zh) *	2021-11-12	2022-03-25	南京艾迪医药科技有限公司	多环氨基甲酰基吡啶酮衍生物及其制备方法和药物组合物
EP4441238A1 (en)	2021-12-03	2024-10-09	VIIV Healthcare Company	Process of synthesizing (r)-3-aminobutan-1-ol
TW202446773A (zh)	2022-04-06	2024-12-01	美商基利科學股份有限公司	橋聯三環胺甲醯基吡啶酮化合物及其用途
US20240270756A1 (en) *	2023-01-18	2024-08-15	Ascletis Bioscience Co., Ltd.	Integrase Inhibitor and Use Thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3959316A (en) *	1972-03-13	1976-05-25	Snam Progetti S.P.A.	Procedure for propylene oxide synthesis
JPH0296506A (ja) *	1988-09-30	1990-04-09	Daicel Chem Ind Ltd	除草剤組成物
JP2533796B2 (ja)	1988-10-18	1996-09-11	ダイセル化学工業株式会社	５−アルコキシピリジン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
JP2551472B2 (ja) *	1988-10-18	1996-11-06	ダイセル化学工業株式会社	５−アルコキシ−γ−ピロン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
HUP0101999A3 (en)	1997-12-22	2003-06-30	Upjohn Co	4-hydroxyquinoline-3-carboxamides and hydrazides use of them and pharmaceutical compositions containing them
EP1297834A4 (en) †	2000-06-14	2007-05-09	Shionogi & Co	ENZYME INHIBITOR HAVING TWO DIVALENT METAL IONS AS ACTIVE CENTERS
US6580562B2 (en)	2000-07-24	2003-06-17	Yazaki Corporation	On-vehicle display unit
US6384263B1 (en)	2000-08-04	2002-05-07	E. I. Du Pont De Nemours And Company	Process for making 3-hydroxyalkanelnitriles and conversion of the 3-hydroxyalkanelnitrile to an hydroxyaminoalkane
AU1532802A (en)	2000-10-12	2002-04-22	Merck & Co Inc	Aza- and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors
JP2003032772A (ja)	2001-07-12	2003-01-31	Foster Electric Co Ltd	耳掛け式イヤホン
KR20100087209A (ko)	2001-08-10	2010-08-03	시오노기세이야쿠가부시키가이샤	항바이러스제
DE122009000048I1 (de)	2001-10-26	2010-04-08	Angeletti P Ist Richerche Bio	N-substituierte hydroxypyrimidinoncarboxamid-hemmer der hiv-integrase
WO2003035076A1 (en)	2001-10-26	2003-05-01	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa	Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
CA2472372C (en)	2002-01-17	2010-08-17	Melissa Egbertson	Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors
WO2004004657A2 (en)	2002-07-09	2004-01-15	Bristol-Myers Squibb Company	Hiv integrase inhibitors
WO2004024693A1 (ja)	2002-08-13	2004-03-25	Shionogi & Co., Ltd.	Ｈｉｖインテグラーゼ阻害活性を有するヘテロ環化合物
EP1549315A4 (en)	2002-09-11	2007-05-23	Merck & Co Inc	DIHYDROXYPYRIDOPYRAZINE-1,6-DION COMPOUNDS AS HIV INTEGRASE INHIBITORS
MXPA05007010A (es)	2002-12-27	2005-08-18	Angeletti P Ist Richerche Bio	Tetrahidro-4h-pirido[1,2-a]pirimidinas y compuestos relacionados utiles como inhibidores de la integrasa del virus de inmunodeficiencia humana.
US6960680B2 (en)	2003-01-08	2005-11-01	Rhodia Chirex, Inc.	Manufacture of water-soluble β-hydroxynitriles
JP2004244320A (ja)	2003-02-10	2004-09-02	Shionogi & Co Ltd	含窒素複素環抗ウイルス剤
EP1622615A4 (en)	2003-05-13	2009-02-18	Smithkline Beecham Corp	INHIBITORS OF THE INTEGRASE OF NAPHTHYRIDINE
AU2003273190A1 (en) *	2003-08-12	2005-02-25	Rachel Beijer	Scheduled message service
TW200510425A (en) *	2003-08-13	2005-03-16	Japan Tobacco Inc	Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
JP4530642B2 (ja)	2003-10-31	2010-08-25	オリンパス株式会社	内視鏡装置
WO2005077050A2 (en)	2004-02-11	2005-08-25	Smithkline Beecham Corporation	Hiv integrase inhibitors
JP2007528379A (ja)	2004-03-09	2007-10-11	イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー	Ｈｉｖインテグラーゼ阻害薬
CA2557785A1 (en)	2004-03-09	2005-10-06	Merck & Co. Inc.	Hiv integrase inhibitors
EP1756114B1 (en)	2004-05-07	2014-11-19	Merck Sharp & Dohme Corp.	Hiv integrase inhibitors
EP1973906A1 (en)	2004-12-23	2008-10-01	Virochem Pharma Inc.	Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase
US7858788B2 (en) *	2005-02-21	2010-12-28	Shionogi & Co., Ltd.	Bicyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
CA2600832C (en) *	2005-03-31	2011-12-13	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A.	Hiv integrase inhibitors
PL3045206T3 (pl) *	2005-04-28	2018-08-31	Viiv Healthcare Company	Wielopierścieniowe pochodne karbamoilopirydonu wykazujące aktywność inhibitorową wobec integrazy HIV
JP2005312076A (ja)	2005-05-26	2005-11-04	Olympus Corp	電子撮像装置
WO2007019098A2 (en)	2005-08-04	2007-02-15	Smithkline Beecham Corporation	Hiv integrase inhibitors
BRPI0617842A2 (pt) *	2005-10-27	2011-08-09	Shionogi & Co	composto ou um sal farmaceuticamente aceitável ou um solvato do mesmo, e, composição farmacêutica

2006
- 2006-04-28 PL PL16154531T patent/PL3045206T3/pl unknown
- 2006-04-28 KR KR1020157036007A patent/KR101848819B1/ko active IP Right Review Request
- 2006-04-28 KR KR1020077027734A patent/KR101363875B1/ko active IP Right Review Request
- 2006-04-28 DK DK18166621.5T patent/DK3372281T3/da active
- 2006-04-28 PT PT121590822T patent/PT2465580E/pt unknown
- 2006-04-28 NZ NZ562339A patent/NZ562339A/en unknown
- 2006-04-28 ES ES12159082.2T patent/ES2446324T3/es active Active
- 2006-04-28 LT LTEP16154531.4T patent/LT3045206T/lt unknown
- 2006-04-28 KR KR1020137028203A patent/KR101504998B1/ko active IP Right Grant
- 2006-04-28 BR BRPI0610030A patent/BRPI0610030B8/pt active IP Right Grant
- 2006-04-28 ES ES18166621T patent/ES2892304T3/es active Active
- 2006-04-28 EP EP17156763.9A patent/EP3187226A1/en not_active Withdrawn
- 2006-04-28 LT LTEP18166621.5T patent/LT3372281T/lt unknown
- 2006-04-28 EP EP17156762.1A patent/EP3187225B1/en not_active Not-in-force
- 2006-04-28 EP EP12159082.2A patent/EP2465580B1/en active Active
- 2006-04-28 EP EP06758843.4A patent/EP1874117B8/en active Active
- 2006-04-28 EP EP18166621.5A patent/EP3372281B1/en active Active
- 2006-04-28 EP EP17195276.5A patent/EP3284519A1/en not_active Withdrawn
- 2006-04-28 ES ES12159079.8T patent/ES2567197T3/es active Active
- 2006-04-28 PL PL17195280T patent/PL3284520T3/pl unknown
- 2006-04-28 DK DK16154531.4T patent/DK3045206T3/en active
- 2006-04-28 SI SI200632268T patent/SI3045206T1/en unknown
- 2006-04-28 SI SI200632418T patent/SI3187225T1/sl unknown
- 2006-04-28 JP JP2008509227A patent/JP4295353B2/ja active Active
- 2006-04-28 DK DK17156762.1T patent/DK3187225T3/da active
- 2006-04-28 ES ES16154531T patent/ES2667868T5/es active Active
- 2006-04-28 HU HUE17195280 patent/HUE044978T2/hu unknown
- 2006-04-28 DK DK06758843.4T patent/DK1874117T3/da active
- 2006-04-28 DK DK12159082.2T patent/DK2465580T3/en active
- 2006-04-28 DK DK17195280.7T patent/DK3284520T3/da active
- 2006-04-28 PL PL18166621T patent/PL3372281T3/pl unknown
- 2006-04-28 SI SI200631703T patent/SI1874117T1/sl unknown
- 2006-04-28 ES ES06758843.4T patent/ES2437268T3/es active Active
- 2006-04-28 TW TW095115285A patent/TWI378931B/zh active
- 2006-04-28 PT PT161545314T patent/PT3045206T/pt unknown
- 2006-04-28 WO PCT/US2006/016604 patent/WO2006116764A1/en active Application Filing
- 2006-04-28 PT PT67588434T patent/PT1874117E/pt unknown
- 2006-04-28 ES ES17156762T patent/ES2906792T3/es active Active
- 2006-04-28 AU AU2006239177A patent/AU2006239177B8/en active Active
- 2006-04-28 PL PL06758843T patent/PL1874117T3/pl unknown
- 2006-04-28 US US11/919,386 patent/US8129385B2/en active Active
- 2006-04-28 PT PT17195280T patent/PT3284520T/pt unknown
- 2006-04-28 ES ES17195280T patent/ES2743531T3/es active Active
- 2006-04-28 PT PT181666215T patent/PT3372281T/pt unknown
- 2006-04-28 SI SI200631747T patent/SI2465580T1/sl unknown
- 2006-04-28 KR KR1020147017235A patent/KR101580310B1/ko active IP Right Grant
- 2006-04-28 HU HUE18166621A patent/HUE056603T2/hu unknown
- 2006-04-28 HU HUE16154531A patent/HUE037795T2/hu unknown
- 2006-04-28 EP EP12159079.8A patent/EP2527007B1/en active Active
- 2006-04-28 VN VN201300151A patent/VN34404A1/vi unknown
- 2006-04-28 MX MX2007013351A patent/MX302718B/es active IP Right Grant
- 2006-04-28 PL PL12159082T patent/PL2465580T3/pl unknown
- 2006-04-28 EP EP16154531.4A patent/EP3045206B2/en active Active
- 2006-04-28 SI SI200632410T patent/SI3372281T1/sl unknown
- 2006-04-28 LT LTEP17195280.7T patent/LT3284520T/lt unknown
- 2006-04-28 EA EA200702080A patent/EA014162B1/ru active Protection Beyond IP Right Term
- 2006-04-28 SI SI200632344T patent/SI3284520T1/sl unknown
- 2006-04-28 EP EP17195280.7A patent/EP3284520B1/en active Active
- 2006-04-28 CA CA2606282A patent/CA2606282C/en active Active
2007
- 2007-10-10 IL IL186555A patent/IL186555A/en active IP Right Grant
- 2007-10-10 NO NO20075165A patent/NO339525B1/no active Protection Beyond IP Right Term
- 2007-10-25 MX MX2011010484A patent/MX312216B/es unknown
- 2007-11-20 MA MA30388A patent/MA29460B1/fr unknown
2008
- 2008-01-24 HK HK08100942.1A patent/HK1107227A1/xx unknown
- 2008-10-08 JP JP2008261344A patent/JP2009079058A/ja active Pending
2011
- 2011-10-23 IL IL215788A patent/IL215788A0/en unknown
2012
- 2012-01-18 US US13/352,686 patent/US8410103B2/en active Active
- 2012-12-18 HK HK12113039.2A patent/HK1172282A1/xx unknown
2013
- 2013-02-08 US US13/763,174 patent/US8778943B2/en active Active
- 2013-03-14 IL IL225207A patent/IL225207A/en active IP Right Review Request
- 2013-03-14 IL IL225206A patent/IL225206A/en active IP Right Grant
- 2013-11-27 CY CY20131101061T patent/CY1115151T1/el unknown
2014
- 2014-03-13 CY CY20141100201T patent/CY1116331T1/el unknown
- 2014-03-14 US US14/211,364 patent/US9051337B2/en active Active
- 2014-05-07 LU LU92446C patent/LU92446I2/xx unknown
- 2014-05-19 FR FR14C0041C patent/FR14C0041I2/fr active Active
- 2014-06-25 CY CY2014024C patent/CY2014024I1/el unknown
- 2014-07-03 NL NL300676C patent/NL300676I2/nl unknown
- 2014-07-09 HU HUS1400039C patent/HUS1400039I1/hu unknown
2015
- 2015-04-30 US US14/700,679 patent/US9273065B2/en active Active
2016
- 2016-01-20 US US15/001,336 patent/US20160137666A1/en not_active Abandoned
- 2016-03-31 US US15/086,616 patent/US20160207939A1/en not_active Abandoned
- 2016-06-29 US US15/196,245 patent/US20160304535A1/en not_active Abandoned
- 2016-08-18 NO NO20161315A patent/NO340111B1/no active Protection Beyond IP Right Term
- 2016-10-11 US US15/290,094 patent/US20170029438A1/en not_active Abandoned
2017
- 2017-02-08 US US15/427,184 patent/US20170145033A1/en not_active Abandoned
- 2017-03-27 NO NO2017010C patent/NO2017010I2/no unknown
- 2017-04-10 US US15/482,896 patent/US20170209454A1/en not_active Abandoned
- 2017-04-27 US US15/498,667 patent/US20170224694A1/en not_active Abandoned
- 2017-04-27 US US15/498,684 patent/US20170224695A1/en not_active Abandoned
- 2017-05-17 US US15/597,343 patent/US20170253616A1/en not_active Abandoned
- 2017-05-18 US US15/598,655 patent/US20170260203A1/en not_active Abandoned
- 2017-05-18 US US15/598,671 patent/US20170267693A1/en not_active Abandoned
- 2017-09-07 US US15/697,847 patent/US20170369509A1/en not_active Abandoned
2018
- 2018-06-19 CY CY20181100633T patent/CY1120345T1/el unknown
- 2018-07-16 HK HK18109159.8A patent/HK1249742A1/zh unknown
- 2018-08-16 HK HK18110519.1A patent/HK1251191A1/zh unknown
2019
- 2019-01-10 US US16/244,441 patent/US20190152990A1/en not_active Abandoned
- 2019-05-01 US US16/400,373 patent/US10927129B2/en active Active
- 2019-08-20 CY CY20191100891T patent/CY1122052T1/el unknown
2020
- 2020-07-09 US US16/924,390 patent/US11267823B2/en active Active
2021
- 2021-05-10 NO NO2021018C patent/NO2021018I1/no unknown
- 2021-05-26 CY CY2021016C patent/CY2021016I2/el unknown
- 2021-06-08 NL NL301109C patent/NL301109I1/nl unknown
- 2021-06-10 FI FIC20210017C patent/FIC20210017I1/fi unknown
- 2021-06-14 HU HUS2100023C patent/HUS2100023I1/hu unknown
- 2021-06-14 HU HUS2100022C patent/HUS2100022I1/hu unknown
- 2021-06-15 LU LU00210C patent/LUC00210I2/en unknown
- 2021-06-16 LT LTPA2021512C patent/LTC2465580I2/lt unknown
- 2021-10-06 CY CY20211100866T patent/CY1124601T1/el unknown
2022
- 2022-01-27 US US17/586,006 patent/US20220213121A1/en not_active Abandoned
2023
- 2023-11-08 NO NO2023042C patent/NO2023042I1/no unknown
2024
- 2024-04-09 US US18/630,561 patent/US20240279238A1/en active Pending

Also Published As

Publication number	Publication date
EP1874117A1 (en)	2008-01-09
SI3187225T1 (sl)	2022-04-29
DK3372281T3 (da)	2021-09-27
SI3372281T1 (sl)	2021-11-30
PL1874117T3 (pl)	2014-01-31
EP2465580B1 (en)	2013-12-18
EA200702080A1 (ru)	2008-04-28
PT3284520T (pt)	2019-09-10
HUS1400039I1 (hu)	2016-08-29
HK1107227A1 (en)	2008-04-03
US20170209454A1 (en)	2017-07-27
IL186555A0 (en)	2008-01-20
LT3045206T (lt)	2018-06-11
US20240279238A1 (en)	2024-08-22
US20200339598A1 (en)	2020-10-29
US20170260203A1 (en)	2017-09-14
US20190284208A1 (en)	2019-09-19
JP4295353B2 (ja)	2009-07-15
US20130172559A1 (en)	2013-07-04
EP3284519A8 (en)	2018-04-18
SI3284520T1 (sl)	2019-10-30
PT1874117E (pt)	2013-10-17
KR101363875B1 (ko)	2014-02-21
NO2017010I1 (no)	2017-03-27
NL301109I2 (nl)	2021-09-15
MX312216B (en)	2013-08-12
US20220213121A1 (en)	2022-07-07
NL301109I1 (nl)	2021-09-15
EP1874117B8 (en)	2014-03-12
HUS2100023I1 (hu)	2021-07-28
AU2006239177B2 (en)	2011-10-20
EP3284519A1 (en)	2018-02-21
DK2465580T3 (en)	2014-03-10
US20120115875A1 (en)	2012-05-10
PT3372281T (pt)	2021-10-14
NO20075165L (no)	2007-11-22
JP2009079058A (ja)	2009-04-16
KR20140097438A (ko)	2014-08-06
EP3372281A1 (en)	2018-09-12
EP2465580A1 (en)	2012-06-20
KR20080009733A (ko)	2008-01-29
LT3372281T (lt)	2021-12-10
FIC20210017I1 (fi)	2021-06-10
MX302718B (es)	2012-08-27
KR101848819B1 (ko)	2018-04-16
LT3284520T (lt)	2019-09-25
ES2743531T3 (es)	2020-02-19
PL3372281T3 (pl)	2021-12-27
HUE044978T2 (hu)	2019-11-28
US8778943B2 (en)	2014-07-15
KR101504998B1 (ko)	2015-03-23
US9273065B2 (en)	2016-03-01
PT3045206T (pt)	2018-07-05
HK1249742A1 (zh)	2018-11-09
CY1116331T1 (el)	2017-02-08
US20170029438A1 (en)	2017-02-02
NO339525B1 (no)	2016-12-27
US20170224695A1 (en)	2017-08-10
EP3284520B1 (en)	2019-06-05
ES2667868T5 (es)	2023-06-01
PL2465580T3 (pl)	2014-05-30
KR20130133061A (ko)	2013-12-05
PT2465580E (pt)	2014-02-25
HUE056603T2 (hu)	2022-02-28
CY2014024I2 (el)	2015-12-09
EP3045206A1 (en)	2016-07-20
EP3187225A1 (en)	2017-07-05
CY1124601T1 (el)	2022-07-22
AU2006239177B8 (en)	2012-02-16
US20170253616A1 (en)	2017-09-07
CY1122052T1 (el)	2020-10-14
EP1874117A4 (en)	2009-12-30
BRPI0610030A2 (pt)	2011-10-11
US10927129B2 (en)	2021-02-23
US20170369509A1 (en)	2017-12-28
DK3187225T3 (da)	2022-02-28
HUS2100022I1 (hu)	2021-07-28
IL225207A (en)	2017-11-30
SI3045206T1 (en)	2018-07-31
CY1120345T1 (el)	2019-07-10
US20170224694A1 (en)	2017-08-10
EP3187225B1 (en)	2022-01-05
DK3284520T3 (da)	2019-09-16
US20170145033A1 (en)	2017-05-25
HUE037795T2 (hu)	2018-09-28
US20190152990A1 (en)	2019-05-23
LTC2465580I2 (xx)	2022-10-10
NO340111B1 (no)	2017-03-13
US20160304535A1 (en)	2016-10-20
US20150232479A1 (en)	2015-08-20
US9051337B2 (en)	2015-06-09
LTPA2021512I1 (xx)	2021-07-12
EP2527007B1 (en)	2016-03-30
NO2023042I1 (no)	2023-11-08
US20160207939A1 (en)	2016-07-21
CY2021016I1 (el)	2021-10-15
DK3045206T3 (en)	2018-05-22
MA29460B1 (fr)	2008-05-02
HK1172282A1 (en)	2013-04-19
CY2014024I1 (el)	2015-12-09
US20140200209A1 (en)	2014-07-17
US20090318421A1 (en)	2009-12-24
BRPI0610030B1 (pt)	2020-09-15
CA2606282C (en)	2016-04-26
NL300676I2 (xx)	2016-10-11
EA014162B1 (ru)	2010-10-29
IL225206A (en)	2017-11-30
EP3045206B2 (en)	2023-02-15
CY1115151T1 (el)	2015-12-09
ES2667868T3 (es)	2018-05-14
ES2906792T3 (es)	2022-04-20
KR20160003889A (ko)	2016-01-11
ES2437268T3 (es)	2014-01-09
FR14C0041I1 (xx)	2014-06-27
EP3045206B1 (en)	2018-03-28
CA2606282A1 (en)	2006-11-02
FR14C0041I2 (fr)	2015-11-13
JP2008540343A (ja)	2008-11-20
US11267823B2 (en)	2022-03-08
KR101580310B1 (ko)	2016-01-04
TW200716635A (en)	2007-05-01
NZ562339A (en)	2011-01-28
SI2465580T1 (sl)	2014-04-30
IL215788A0 (en)	2011-12-29
EP3372281B1 (en)	2021-07-07
NO20161315A1 (no)	2007-11-22
ES2567197T3 (es)	2016-04-20
NO2021018I1 (no)	2021-05-10
PL3284520T3 (pl)	2020-01-31
ES2892304T3 (es)	2022-02-03
US8410103B2 (en)	2013-04-02
ES2446324T3 (es)	2014-03-07
EP2527007A1 (en)	2012-11-28
DK1874117T3 (da)	2013-09-23
EP3187226A1 (en)	2017-07-05
EP1874117B1 (en)	2013-08-28
IL186555A (en)	2016-10-31
BRPI0610030B8 (pt)	2022-01-11
US20160137666A1 (en)	2016-05-19
TWI378931B (en)	2012-12-11
US20170267693A1 (en)	2017-09-21
AU2006239177A1 (en)	2006-11-02
WO2006116764A1 (en)	2006-11-02
VN34404A1 (en)	2013-07-25
HK1251191A1 (zh)	2019-01-25
MX2007013351A (es)	2008-01-21
US8129385B2 (en)	2012-03-06
NO2017010I2 (no)	2017-03-27
SI1874117T1 (sl)	2014-01-31
LUC00210I2 (xx)	2022-10-07
CY2021016I2 (el)	2021-12-31
EP3284520A1 (en)	2018-02-21
PL3045206T3 (pl)	2018-08-31

Publication	Publication Date	Title
LU92446I2 (fr)	2015-10-29	Dolutégravir ou un sel ou solvate pharmaceutiquement acceptable de celui-ci, y compris de dolutégravir de sodium
LU93327I2 (fr)	2017-01-30	Opicapone ou un sel pharmaceutiquement acceptable de celui-ci
LU92568I2 (fr)	2015-10-29	Siméprévir, ou un sel de celui-ci, y compris le sodium siméprévir
NO2024010I1 (no)	2024-03-06	Gefapixant, or a pharmaceutically acceptable salt thereof
NO2023047I1 (no)	2023-12-21	Cedazuridine, or a pharmaceutically acceptable salt thereof
LU92702I2 (fr)	2016-07-29	Naloxegol ou un sel pharmaceutiquement acceptable de celui-ci (moventig)
NO2022057I1 (no)	2022-12-13	Capmatinib or a pharmaceutically acceptable salt thereof
LU92137I2 (fr)	2014-01-18	Ruxolitinib, ou un de ses sels pharmaceutiquement acceptables
NO2020038I1 (no)	2020-11-18	Ozanimod, or a pharmaceutically acceptable salt thereof, including the hydrochloride salt
LU92883I2 (fr)	2016-01-20	Sonidégib ou un sel, hydrate ou solvate pharmaceutiquement acceptable qui en dérive
NL301106I1 (nl)	2021-06-02	Cenobamaat of een farmaceutisch aanvaardbaar zout daarvan
LU93180I2 (fr)	2016-10-18	Alirocumab ou un dérivé pharmaceutiquement acceptable de celui-ci (PRALUENT)
LU93312I2 (fr)	2017-01-26	Migalastat ou un sel de celui-ci, y compris le sel de chlorhydrate
NO2022022I1 (no)	2022-06-09	Fedratinib, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable hydrate thereof, in particular fedratinib dihydrochloride monohydrate
NL300974I2 (nl)	2022-04-06	Binimetinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of solvaat
LU92785I2 (fr)	2015-11-03	Céritinib ou un sel pharamceutiquement acceptable de celui-ci
NO2013008I1 (no)	2013-04-29	Krizotinib eller et farmasøytisk akseptabelt salt,hydrat eller solvat derav
NL300703I2 (nl)	2017-07-20	Simeprevir, of een farmaceutisch aanvaardbaar zout daarvan, waaronder simeprevirnatrium.
NO2018016I2 (no)	2018-05-14	Niraparib eller et farmasøytisk akseptabelt salt, stereoisomer eller tautomer derav
LU92512I2 (fr)	2014-10-06	Afoxolaner, ou un oxyde nitrique de celui-ci, ou un sel pharmaceutiquement acceptable de celui-ci
NO2016016I1 (no)	2016-08-17	Lesinurad, eller et farmasøytisk akseptabelt salt derav
LU91962I2 (fr)	2012-05-21	Azilsartan medoxomil (INN) et un de ses sels pharmaceutiquement acceptable, y compris le sel de potassium
GB0624471D0 (en)	2007-01-17	Merocyanine Derivatives
EP1721905A4 (en)	2009-11-18	thiazole
IL190608A0 (en)	2008-11-03	5-(arylsulfonyl)-pyrazolopiperidines